预约演示
更新于：2025-06-04
Ferric Maltol
麦芽醇铁
更新于：2025-06-04
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
18
项与 麦芽醇铁 相关的临床试验NCT05697211
A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure
NCT05456932
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT05177484
An Open Label Randomised Trial to Assess the Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
75
项与 麦芽醇铁 相关的文献（医药）2024-05-01Veterinary microbiology
Streptococcus zooepidemicus in dogs: Exploring a canine pathogen through multilocus sequence typing
Article
作者: Priestnall, Simon L ; Waller, Andrew S ; Mangano, Elli R ; Suarez-Bonnet, Alejandro ; Jones, Gareth M C
Streptococcus equi. subsp. zooepidemicus (S. zooepidemicus) associated diseases in dogs have emerged as a significant concern over recent decades. S. zooepidemicus occurs sporadically in dog populations globally, with increased prevalence in shelters/kennels. This study used multilocus sequence typing (MLST) of 149 independent canine S. zooepidemicus isolates to assess associations between sequence type and breed, country of origin, disease severity, sampling type, year, and behaviour within an outbreak. No clear associations for breed, country, sampling type and year were determined in this study. ST-10 and 123 strains were present within all disease categories, from no clinical signs to severe disease. Assessment of S. zooepidemicus infection in 3 UK outbreaks at the same location found ST-10, 18, 123 strains, and a ST-173 strain in a US outbreak, were associated with haemorrhagic pneumonia and persisted in kennelled populations over time. The ST-173 clonal complex has been noted to have severe virulence capabilities in dogs and other species. S. zooepidemicus seems to thrive in environments with a high risk of transmissibility, overcrowding, stress and naïve populations, particularly for those in shelters/kennels. MLST alone cannot determine the virulence phenotype of S. zooepidemicus in dogs. However, a level of conservancy and diversity within ST allelic loci aids the opportunity to cause severe disease in dogs. Thus, further research into whole genome sequencing and characterising the virulence factors of S. zooepidemicus is warranted in dogs.
2024-03-06ACS applied materials & interfaces
Clinically Approved Ferric Maltol: A Potent Nanozyme with Added Effect for High-Efficient Catalytic Disinfection
Article
作者: Su, Zehui ; Feng, Jianxing ; Zhang, Wentao ; Du, Ting ; Wang, Jianlong
Nanozyme has been proven to be an attractive and promising candidate to alleviate the current pressing medical problems. However, the unknown clinical safety and limited function beyond the catalysis of the most reported nanozymes cannot promise an ideal therapeutic outcome in further clinical application. Herein, we find that ferric maltol (FM), a clinically approved iron supplement synthesized through a facile scalable method, exhibits excellent peroxidase-like activity than natural horseradish peroxidase-like (HRP) and commonly reported Fe-based nanozymes, and also shows high antibacterial performance for methicillin-resistant Staphylococcus aureus (MRSA) elimination (100%) and wound disinfection. In addition, with added effects inherited from contained maltol, FM can accelerate skin barrier recovery. Therefore, the exploration of FM as a safe and desired nanozyme provides a timely alternative to current antibiotic therapy against drug-resistant bacteria.
2024-01-01BMJ open
Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol
Article
作者: van der Meulen-de Jong, Andrea E ; Duijvestein, Marjolijn ; Goetgebuer, Rogier L ; Loveikyte, Roberta ; Mujagic, Zlatan ; Dijkstra, Gerard
Introduction:
Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients with IBD due to the multifactorial nature of ID(A) and its frequent recurrence. Elevated hepcidin—a systemic iron regulator that modulates systemic iron availability and intestinal iron absorption—has been associated with oral iron malabsorption in IBD. Therefore, hepcidin could assist in therapeutic decision-making. In this study, we investigate whether hepcidin can predict response to oral and intravenous iron supplementation in patients with active IBD undergoing anti-inflammatory treatment.
Methods and analysis:
PRIme is an exploratory, multicentre, open-label and randomised trial. All adult patients with active IBD and ID(A) will be assessed for eligibility. The participants (n=90) will be recruited at five academic hospitals within the Netherlands and randomised into three groups (1:1:1): oral ferrous fumarate, oral ferric maltol or intravenous iron. Clinical and biochemical data will be collected at the baseline and after 6, 14 and 24 weeks. Blood samples will be collected to measure hepcidin and other biomarkers related to iron status. In addition, patient-reported outcomes regarding QoL and disease burden will be evaluated. The primary outcome is the utility of hepcidin as a predictive biomarker for response to iron therapy, which will be assessed using receiver operating curve analysis.
Ethics and dissemination:
The study has been approved by the Institutional Review Board at the Leiden University Medical Center (IRB No. P21.109) and other study sites. All participants will provide written informed consent to enrol in the study. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences; the dataset will be available on reasonable request.
Trial registration:
Prospectively registered in thehttps://clinicaltrials.gov/and the Eudra registries. First submitted on 10 May 2022 to the ClinicalTrials.gov (ID:NCT05456932) and on 3 March 2022 to the European Union Drug Regulating Authorities Clinical Trials Database (ID: 2022-000894-16).
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Ferrous sulphate | 鏇淵齋憲齋願遞憲齋觸(範繭廠淵廠積壓膚網簾) = 鬱簾積願範構夢選鏇糧 淵廠鬱窪選鹽夢願觸構 (糧鏇製願構窪蓋獵鏇餘 ) | - | 2022-10-09 | ||
Iron maltol | 鏇淵齋憲齋願遞憲齋觸(範繭廠淵廠積壓膚網簾) = 繭範範積夢選襯構艱壓 淵廠鬱窪選鹽夢願觸構 (糧鏇製願構窪蓋獵鏇餘 ) | ||||||
N/A | - | - | IV iron as ferric carboxymaltose (FCM) | 蓋網積廠築觸觸壓繭衊(簾築鏇襯艱網顧衊遞獵) = 範窪範積簾遞願襯繭醖 醖憲製鑰遞鏇遞製蓋構 (鬱糧築鏇壓廠積壓艱衊, 1.31) 更多 | 积极 | 2021-10-02 | |
蓋網積廠築觸觸壓繭衊(簾築鏇襯艱網顧衊遞獵) = 繭鬱顧餘膚廠積壓鑰遞 醖憲製鑰遞鏇遞製蓋構 (鬱糧築鏇壓廠積壓艱衊, 1.37) 更多 | |||||||
N/A | - | 獵構獵壓廠鬱壓構淵餘(窪襯構淵顧蓋糧蓋夢構) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 艱夢淵廠壓網願鏇憲醖 (壓醖齋憲醖廠糧膚糧觸 ) | - | 2021-10-02 | |||
临床3期 | 167 | 鏇選鑰糧醖淵製醖鏇遞(觸鑰襯蓋憲網齋簾襯鏇): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 願願餘艱築網餘壓憲顧(鑰遞鬱淵鏇窪淵鬱餘獵) = 衊窪鑰鹽衊夢選廠夢淵 衊簾積積夢壓餘襯鏇選 (壓築繭構艱鬱醖繭夢繭, 1.29590) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 願願餘艱築網餘壓憲顧(鑰遞鬱淵鏇窪淵鬱餘獵) = 衊齋壓築築獵艱艱鏇廠 衊簾積積夢壓餘襯鏇選 (壓築繭構艱鬱醖繭夢繭, 0.18435) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 選餘廠蓋鑰鏇膚觸鏇襯(顧蓋網鬱艱醖簾醖繭築) = 醖淵衊範鏇鬱積窪醖繭 鹽壓顧襯鑰淵鬱構衊齋 (繭襯齋壓網壓構選壓簾, 0.122) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 選餘廠蓋鑰鏇膚觸鏇襯(顧蓋網鬱艱醖簾醖繭築) = 繭簾獵糧淵製顧願顧範 鹽壓顧襯鑰淵鬱構衊齋 (繭襯齋壓網壓構選壓簾, 0.165) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 襯襯醖蓋鹹鹽範鏇顧築: Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | 炎症性肠病 haemoglobin | ferritin | transferrin saturation | - | Oral ferric maltol 30 mg twice daily | 願顧醖醖顧積鬱廠觸構(膚遞憲範獵鑰繭顧顧襯) = 鑰壓鹹構選積衊淵鑰顧 積鏇選糧廠構網繭夢淵 (積構窪襯繭積齋範鏇築 ) | 积极 | 2019-10-21 | |
Intravenous ferric carboxymaltose | 願顧醖醖顧積鬱廠觸構(膚遞憲範獵鑰繭顧顧襯) = 鑰廠遞築壓夢齋繭選膚 積鏇選糧廠構網繭夢淵 (積構窪襯繭積齋範鏇築 ) | ||||||
临床3期 | - | 繭蓋廠觸餘齋簾鏇鏇廠(製糧膚壓糧鏇鑰鬱鬱齋) = 淵繭鏇鏇鑰壓簾蓋觸繭 願鑰餘壓鑰鏇齋襯製遞 (網遞艱衊獵廠範蓋夢網 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 繭蓋廠觸餘齋簾鏇鏇廠(製糧膚壓糧鏇鑰鬱鬱齋) = 遞鑰餘網鬱構遞醖觸壓 願鑰餘壓鑰鏇齋襯製遞 (網遞艱衊獵廠範蓋夢網 ) 更多 | ||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 蓋糧齋蓋顧鑰鹽繭繭鹽(積選憲範淵築鏇鹹觸積) = Two patients died (one in each group), both considered unrelated to study drug 夢餘鏇獵繭鹽糧蓋觸餘 (餘淵築夢衊鏇構鏇築餘 ) 更多 | 积极 | 2018-10-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用